Co-Diagnostics Q3 2026 earnings

CODX · 2026-11-10 08:02 BMO ET · 8-K on SEC

Revenue more than doubled YoY, but operating losses widened due to higher costs and a tax benefit reversal.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$282.9M+94.6%+70.2%Ex. 99.1, income statement
EPS (GAAP)-$1.01+78.4%+30.7%Ex. 99.1, income statement
Net income-$6.3M+7.0%+0.4%Ex. 99.1, income statement
Adj. EBITDA-$2.0M+94.6%+70.2%Ex. 99.1, income statement
Adj. EBITDA margin-0.7%+1.3 pp+0.5 ppEx. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin -7.2% (prior -22.4%, change +15.2 pp)
  • Operating expenses $6.2M (+12.5% YoY)
  • One-offs in the quarter Income tax provision $500 (vs $1.2M benefit YoY); Gain on remeasurement of acquisition contingencies $60.4M; Loss on equity method investment in joint ventures $100.0M
  • Effective tax rate 0.0% (prior -16.4%, year-to-date 0.0%)
  • Non-GAAP bridge Depreciation, amortization, interest, stock-based compensation, contingent consideration, realized gains/losses on investments

KPIs

MetricActualPrior quarterPrior yearChange
Product revenue$282.9M$166.1M$145.4M+70.2% QoQ, +94.6% YoY
Weighted average shares outstanding6.3M4.3M1.3M+46.5% QoQ, +397.6% YoY

Guidance

not stated in the 8-K

What drove it

  • Revenue story Product revenue increased 94.6% YoY to $282.9M, driven by a 70.2% QoQ increase.
  • EPS story EPS improved from -$4.66 to -$1.01 YoY due to higher revenue and a tax benefit reversal.
  • One-off check Income tax provision $500 (vs $1.2M benefit YoY); Gain on remeasurement of acquisition contingencies $60.4M; Loss on equity method investment in joint ventures $100.0M

The good

  • Revenue more than doubled YoY (+94.6%)
  • Adj. EBITDA margin improved by 1.3 pp YoY

The bad

  • Operating expenses increased 12.5% YoY
  • Cost of revenue ($303.3M) exceeded revenue ($282.9M)
  • Loss on equity method investment in joint ventures ($100.0M)

The ugly

  • none

Open questions

  • What caused the $100.0M loss on equity method investment in joint ventures?
  • What caused the $60.4M gain on remeasurement of acquisition contingencies?
  • Why did the company issue 3.2M additional shares in Q3 (from 4.3M to 6.3M outstanding)?
Full release

Co-Diagnostics (CODX) earnings release, November 10, 2026

Co-Diagnostics, Inc. (CODX) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Co-Diagnostics

Reports Third Quarter 2026 Financial Results

Two

Regulatory Submissions Under Review in India and the U.S.

Third

Quarter Operating Expenses Down 12% Year Over Year

Platform

Capabilities Expanding with ReadyGo Collaboration, India Connectivity and Vector Smart Growth

SALT

LAKE CITY, November 10, 2026 – Co-Diagnostics, Inc.

(Nasdaq: CODX)

(“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the third quarter ended September 30, 2026.

Third

Quarter 2026 Business Highlights:

“The third quarter was a period of significant regulatory and operational progress for Co-Diagnostics,” said Dwight Egan, Chief Executive

Officer of Co-Diagnostics. “CoSara completed its clinical performance study for our point-of-care tuberculosis test and submitted it to India’s Central Drugs Standard Control Organization (CDSCO), and together with our August FDA 510(k) submission for the Flu

A/B & RSV test, we now have two regulatory submissions under review in two important markets for our platform.

We also launched our cloud and mobile infrastructure in India, began evaluating blood-based testing with ReadyGo, and completed the first international deployment of Vector Smart. With our submissions in India and the U.S. under review, our focus is on supporting those reviews, advancing our feasibility work with ReadyGo and continuing to grow Vector Smart.”

Recent

Developments:

Third

Quarter 2026 Financial Results:

Conference

Call and Webcast:

Co-Diagnostics will host a conference call and webcast at 4:30 p.m. ET today to review its third quarter 2026 results. The conference call and webcast will be available via:

Webcast: ir.co-dx.com on the

Events & Webcasts page, or accessible directly here

Conference

Call: 1-888-880-3330 (Toll Free) or 1-646-357-8766 (Toll)

The call will be recorded and later made available on the Company’s website.

*The

Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review or authorization by applicable regulatory authorities in the jurisdictions in which clearance or approval is sought, including the US FDA, and is not yet available for sale.

About

Co-Diagnostics, Inc.:

Co-Diagnostics,

Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.

The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules

(DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform

(subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

Non-GAAP

Financial Measures:

This press release contains adjusted EBITDA, a non-GAAP measure defined as net income (loss) adjusted for depreciation, amortization, income tax (benefit) expense, net interest (income) expense, stock-based compensation, change in fair value of contingent consideration, and realized gain (loss) on investments. The Company believes that adjusted EBITDA provides useful information to management and investors relating to its results of operations. The Company’s management uses this non-GAAP measure to compare the Company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

Management does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded in the Company’s financial statements. In order to compensate for these limitations, management presents the non-GAAP financial measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of the net income, the most comparable

GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business.

Forward-Looking

Statements:

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Product revenue282,881145,380
Total revenue282,881145,380
Cost of revenue303,34426,285
Gross profit-20,463119,095
Operating expenses
Sales and marketing579,902568,937
General and administrative1,871,8381,815,945
Research and development3,574,7844,480,678
Depreciation and amortization222,363267,383
Total operating expenses6,248,8877,132,943
Loss from operations-6,269,350-7,013,848
Other income (expense), net
Interest income, net3,12313,194
Realized gain on investments41,542
Gain (loss) on disposition of assets4,000
Gain (loss) on remeasurement of acquisition contingencies60,355-42,345
Loss on equity method investment in joint ventures-100,036-55,959
Total other income (expense), net-36,558-39,568
Loss before income taxes-6,305,908-7,053,416
Income tax provision (benefit)500-1,166,593
Net loss-6,306,408-5,886,823
Other comprehensive loss
Change in net unrealized gains on marketable securities, net of tax-39,180
Total other comprehensive loss$--39,180
Comprehensive loss-6,306,408-5,926,003
Loss per common share:
Basic and Diluted-1.01-4.66
Weighted average shares outstanding:
Basic and Diluted6,272,6351,263,031

Balance Sheet

September 30, 2026 — (Unaudited)

September 30, 2026December 31, 2025
Current assets
Cash and cash equivalents714,80311,884,607
Accounts receivable, net51,828190,375
Inventory, net672,950992,397
Income taxes receivable44,559
Prepaid expenses and other current assets498,517581,527
Total current assets1,938,09813,693,465
Property and equipment, net1,767,7492,272,098
Operating lease right-of-use asset1,531,9861,207,453
Intangible assets, net7,219,0007,219,000
Investment in joint ventures335,015350,569
Total assets12,791,84824,742,585
Current liabilities
Accounts payable937,2941,878,225
Accrued expenses850,200865,301
Operating lease liability, current709,754662,258
Contingent consideration liabilities, current12,572119,036
Deferred revenue2,00014,800
Total current liabilities2,511,8203,539,620
Long-term liabilities
Operating lease liability854,749574,301
Total long-term liabilities854,749574,301
Total liabilities3,366,5694,113,921
Stockholders’ equity
Common stock, $0.001 par value; 100,000,000 shares authorized; 7,450,224 shares issued and 7,288,601 shares outstanding as of September 30, 2026 and 2,256,654 shares issued and 2,095,031 shares outstanding as of December 31, 202572,89367,700
Treasury stock, at cost; 161,623 shares held as of September 30, 2026 and December 31, 2025, respectively-15,575,795-15,575,795
Additional paid-in capital127,031,952116,510,298
Accumulated deficit-102,103,771-80,373,539
Total stockholders’ equity9,425,27920,628,664
Total liabilities and stockholders’ equity12,791,84824,742,585

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by words such as “believes,” “expects,”

“estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include, but are not limited to, statements regarding: (i) the continued development, clinical evaluation, regulatory submission, clearance, authorization, and commercialization... (truncated) and regulatory reviews, including the anticipated timing of CDSCO clearance and the commencement of commercial sales in India; (iii) the Company’s ability to develop, scale, and commercialize its manufacturing capabilities, including through CoSara and CoMira and other third parties;

(iv) anticipated market opportunities and international expansion initiatives; (v) the expected capabilities, differentiation, and adoption of the Company’s platform technologies; and (vi) the Company’s strategic, operational, and growth initiatives generally.

Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. These risks and uncertainties include, among others, risks relating to the timing and outcome of FDA and other regulatory review processes; the possibility that clinical or analytical data may not support regulatory clearance, authorization or commercialization; the Company’s ability to successfully complete product development, manufacturing scale-up and commercialization activities; market acceptance and adoption of the Company’s products and technologies; the Company’s dependence on joint ventures, distributors, manufacturers and other third parties; risks associated with conducting business and obtaining regulatory approvals in international markets; the Company’s ability to obtain additional capital when needed, maintain sufficient liquidity to execute its business plans and continue as a going concern; and competitive and technological developments. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements.

Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any regulatory submission, authorization, commercialization milestone, manufacturing initiative, strategic collaboration, or market opportunity will occur on the timelines anticipated by the Company, or at all, due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission

(SEC) on March 31, 2026, and in our other filings with the SEC. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by applicable law.

Investor

Contact:

Valter

Pinto, Managing Director

KCSA

Strategic Communications

+1

212.896.1254

CODX@KCSA.com

Media

Contact:

Jennifer

Webb

ColtrinMethod

PR jcoltrin@coltrinmethodpr.com

CO-DIAGNOSTICS,

INC. AND SUBSIDIARIES

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Co-Diagnostics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.